Since the first bulletin was circulated on 09 March 2020, there have been a number of important developments in relation to the COVID-19 situation worldwide.
As of 14 March 2020, time:matters, the courier service used for the majority of overseas transport of unrelated donor products, continue to accept requests for all areas apart from mainland China, Israel, and Northern Italy (1). However, significant challenges are anticipated due to developing travel restrictions. Transport of cryopreserved products (cord blood units, CAR-T cells) continues as usual via unaccompanied dry shippers.
There is emerging evidence that COVID-19 severity and mortality is higher in patients with cancer (1, 2). In the likely scenario of community spread of COVID-19 in Australia and New Zealand, BMT programmes need to consider ways to reduce risks to patients and staff. The intention of this document is to summarise recommendations from national and international sources for BMT programmes, and to compile suggestions from the ANZ BMT community for local practices. Heads of BMT programmes in the region have reviewed and contributed to the suggestions below.
To date, recommendations have been circulated from WBMT, WMDA, EBMT and ABMDR regarding donors and recipients of HPC. These are summarised in the Table. The WMDA share site (share.wmda.info) has the most detailed information regarding donors and impact on registry operations.